|Update of 14 November 2019:: The applicant for Hopveus has requested a re-examination of EMA’s October 2019 opinion. Upon receipt of the grounds of the request, the Agency will re-examine its opinion and issue a final recommendation.|
The European Medicines Agency has recommended the refusal of the marketing authorisation for Hopveus, a medicine intended for the treatment of alcohol dependence.
The Agency issued its opinion on 17 October 2019. The company that applied for authorisation, D&A Pharma, may ask for re-examination of the opinion within 15 days of receiving the opinion.
|Agency product number||
|International non-proprietary name (INN) or common name||
Substance Withdrawal Syndrome
|Date opinion adopted||